---
title: "Hualan Biological Engineering, Inc. (002007.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/002007.SZ.md"
symbol: "002007.SZ"
name: "Hualan Biological Engineering, Inc."
industry: "Biotechnology"
datetime: "2026-05-21T21:41:11.217Z"
locales:
  - [en](https://longbridge.com/en/quote/002007.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/002007.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/002007.SZ.md)
---

# Hualan Biological Engineering, Inc. (002007.SZ)

## Company Overview

Hualan Biological Engineering Inc., together with its subsidiaries, engages in the research, development, production, and sale of biological products in China and internationally. The company offers blood products, including human serum albumin, human prothrombin complex concentrate, human coagulation factor VIII, human fibrinogen, and freeze-dried human fibrin glue for surgical use, as well as intravenous, human, rabies, hepatitis B, and tetanus immunoglobulin for various therapeutic applications. It also provides vaccine products, such as influenza virus split, H1N1 influenza A virus split, quadrivalent influenza virus split, group A and C meningococcal polysaccharide, group ACYW135 meningococcal polysaccharide, recombinant hepatitis B vaccine, freeze-dried human rabies, and adsorbed tetanus vaccines. In addition, the company develops monoclonal antibody drugs and biosimilars comprising rituximab injection which is in Phase III clinical trials for the treatment of CD20-positive diffuse large B-cell/follicular non-Hodgkin lymphoma and chronic lymphocytic leukemia; adalimumab injection which is in Phase III clinical trials for the treatment of various autoimmune diseases; denosumab injection which is in Phase III clinical trials for the treatment of patients with bone metastases; injectable trastuzumab which is in Phase III clinical trials for the treatment of HER2-positive metastatic/early-stage breast cancer and metastatic gastric cancer; and recombinant Exendin-4-FC fusion protein injection which is in Phase I/II clinical trials for the treatment of type 2 diabetes.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | CN Market |
| Website | [www.hualanbio.com](https://www.hualanbio.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:13.000Z

**Overall: C (0.45)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 24 / 81 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.67% |  |
| Net Profit YoY | -24.72% |  |
| P/B Ratio | 2.16 |  |
| Dividend Ratio | 5.05% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 25298097232.57 |  |
| Revenue | 4480885801.27 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 7.18% | B |
| Profit Margin | 19.10% | A |
| Gross Margin | 50.19% | B |
| Revenue YoY | 0.67% | C |
| Net Profit YoY | -24.72% | D |
| Total Assets YoY | -9.50% | E |
| Net Assets YoY | -3.80% | D |
| Cash Flow Margin | 99.97% | C |
| OCF YoY | 0.67% | C |
| Turnover | 0.28 | D |
| Gearing Ratio | 9.46% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Hualan Biological Engineering, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.67%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-24.72%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.16",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "5.05%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "25298097232.57",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "4480885801.27",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "7.18%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "19.10%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "50.19%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "0.67%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-24.72%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-9.50%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-3.80%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "99.97%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "0.67%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.28",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "9.46%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 29.68 | 10/81 | 29.96 | 28.86 | 25.84 |
| PB | 2.17 | 31/81 | 2.52 | 2.46 | 2.38 |
| PS (TTM) | 5.67 | 27/81 | 6.77 | 6.58 | 6.42 |
| Dividend Yield | 5.03% | 2/81 | 4.61% | 4.40% | 1.23% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Sunshine Guojian Pharmaceutical (688336.SH) | A | A | B | A | B | A |
| 02 | AMOYTOP (688278.SH) | A | A | A | A | B | A |
| 03 | BeOne Medicines (688235.SH) | B | A | B | C | A | B |
| 04 | RemeGen (688331.SH) | A | A | C | C | B | B |
| 05 | Biocytogen (688796.SH) | A | A | E | B | A | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-06T16:00:00.000Z

Total Analysts: **7**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 5 | 71% |
| Overweight | 1 | 14% |
| Hold | 1 | 14% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 13.93 |
| Highest Target | 22.05 |
| Lowest Target | 17.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/002007.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/002007.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/002007.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/002007.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**